Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Molecular Pharmacology

• Publication date

  1998-11-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1124/MOL.54.5.770PMID 9804612
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects on DNA integrity and apoptosis induction by a novel antitumor sesquiterpene drug, 6-hydroxymethylacylfulvene (HMAF, MGI 114).

  1997cited by this paper
• Preferential formation and decreased removal of cisplatin-DNA adducts in Chinese hamster ovary cell mitochondrial DNA as compared to nuclear DNA.

  1997cited by this paper
• Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel.

  1996cited by this paper
• In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells.

  1996influential reference
• Preferential binding of cisplatin to mitochondrial DNA of Chinese hamster ovary cells.

  1995cited by this paper
• Correlation of Gene‐specific Damage with Cisplatin between Human Adenocarcinoma Cells and Peripheral Blood Mononuclear Cells Analyzed by Polymerase Chain Reaction‐stop Assay

  1995influential reference
• Reaction of (1R,2S,3S)-3-methylcyclohexanediamineplatinum(II) with DNA: isolation and characterization of the platinum-nucleotide adducts by means of HPLC and NMR spectroscopy.

  1995cited by this paper
• Cytotoxicity, cellular accumulation and DNA binding of oxaliplatin isomers.

  1995cited by this paper
• Polymerase chain reaction analysis of cisplatin-induced mitochondrial DNA damage in human ovarian carcinoma cells.

  1995influential reference
• Effects of bizelesin (U-77779), a bifunctional alkylating minor groove agent, on genomic and simian virus 40 DNA.

  1995cited by this paper
• The chemistry and biology of platinum complexes with the 1,2-diaminocyclohexane carrier ligand (review).

  1995influential reference
• Formation of DNA adducts by the anticancer drug carboplatin: different nucleotide sequence preferences in vitro and in cells.

  1995cited by this paper
• Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin

  1995cited by this paper
• New Platinum Agents

  1994cited by this paper
• Detection of sequence-specific antitumor alkylating agent DNA damage from cells treated in culture and from a patient.

  1994cited by this paper
• Rapid Polymerase Chain Reaction Assay to Detect Variation in the Extent of Gene‐specific Damage between Cisplatin‐ or VP‐16‐resistant and Sensitive Lung Cancer Cell Lines

  1994influential reference
• New platinum agents. A comparison in ovarian cancer.

  1994cited by this paper
• New Cisplatin Analogues in Development

  1993cited by this paper
• New platinum antitumor complexes.

  1993cited by this paper
• In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin.

  1993cited by this paper
• Repair of mitochondrial DNA after various types of DNA damage in Chinese hamster ovary cells.

  1992cited by this paper
• Analysis of DNA damage and repair in murine leukemia L1210 cells using a quantitative polymerase chain reaction assay

  1992cited by this paper
• The current status of new platinum analogs.

  1992cited by this paper
• Biophysical analysis of DNA modified by 1,2-diaminocyclohexane platinum(II) complexes.

  1992influential reference
• Induction of heat-labile sites in DNA of mammalian cells by the antitumor alkylating drug CC-1065.

  1991cited by this paper
• A polymerase chain reaction-based method to detect cisplatin adducts in specific genes.

  1991cited by this paper
• Comparison of two cytotoxicity assays--tetrazolium derivative reduction (MTT) and tritiated thymidine uptake--on three malignant mouse cell lines using chemotherapeutic agents and investigational drugs.

  1990cited by this paper
• Preferential binding of cisplatin to mitochondrial DNA and suppression of ATP generation in human malignant melanoma cells.

  1990cited by this paper
• Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum.

  1989cited by this paper
• Conversion of monofunctional DNA adducts of cis-diamminedichloroplatinum (II) to bifunctional lesions. Effect on the in vitro replication of single-stranded DNA by Escherichia coli DNA polymerase I and eukaryotic DNA polymerases alpha.

  1989cited by this paper
• Antitumor activity of a new platinum complex, oxalato (trans-l-1,2-diaminocyclohexane)platinum (II): new experimental data.

  1989influential reference
• Characterization of adducts produced in DNA by isomeric 1,2-diaminocyclohexaneplatinum(II) complexes.

  1989influential reference
• Binding of cisplatin to specific sequences of human DNA in vitro.

  1988cited by this paper
• The quantitative detection of various Pt-DNA-adducts in Chinese hamster ovary cells treated with cisplatin: application of immunochemical techniques.

  1985cited by this paper
• New Cisplatin Analogues in Development A Review

  year unknowncited by this paper

• Bio-logical effect on fungi, bacteria and cancer cells with a study of the aging of selenium dioxide particles produced by pulsed laser

  2025cites this paper
• Overcoming therapy resistance in pancreatic cancer: challenges and emerging strategies.

  2025cites this paper
• Causes and consequences of RNA:protein cross-links – lessons from chemotherapy

  2025cites this paper
• An Adverse Outcome Pathway for DNA adduct formation leading to kidney failure.

  2025cites this paper
• The unique Pt(II)-induced nucleolar stress response and its deviation from DNA damage response pathways

  2024cites this paper
• Clinical characteristics and genetic HLA marker for patients with oxaliplatin-induced adverse drug reactions.

  2024cites this paper
• DNA Adducts in Cancer Chemotherapy.

  2024cites this paper
• The Hippo pathway terminal effector TAZ/WWTR1 mediates oxaliplatin sensitivity in p53 proficient colon cancer cells

  2024cites this paper
• The Hippo pathway terminal effector TAZ/WWTR1 mediates oxaliplatin sensitivity in colon cancer cells

  2023cites this paper
• The Hippo pathway terminal effector TAZ/WWTR1 mediates oxaliplatin sensitivity in 1 HCT116 colon cancer cells 2

  2023cites this paper
• Impact du microbiote intestinal dans les cancers colorectaux

  2023cites this paper
• Oxaliplatin and its derivatives – An overview

  2023cites this paper
• Differences in the ultrastructure of neurons in the spinal ganglion and dorsal rootlet between rats treated with cisplatin only versus co‐administration with a sphingosine 1‐phosphate receptor 2 agonist in attenuating neuropathy and allodynia

  2023cites this paper
• Single-Cell and Bulk ICP-MS Investigation of Accumulation Patterns of Pt-based Metallodrugs in Cisplatin-Sensitive and -Resistant Cell Models.

  2022cites this paper
• The immune modifying effects of chemotherapy and advances in chemo-immunotherapy.

  2022cites this paper
• Revisiting the Anti-Cancer Toxicity of Clinically Approved Platinating Derivatives

  2022cites this paper
• Early nucleolar responses differentiate mechanisms of cell death induced by oxaliplatin and cisplatin

  2021cites this paper
• A comparative analysis of the mutagenicity of platinum-containing chemotherapeutic agents reveals direct and indirect mutagenic mechanisms

  2021cites this paper
• Post-Marketing Surveillance of a generic Oxaliplatin (AlvoxalⓇ) in Iranian Patients with Cancer

  2021cites this paper
• The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy

  2021cites this paper
• Conventional Chemotherapy Nephrotoxicity.

  2021cites this paper
• Efficacy of Postoperative FOLFOX Versus XELOX Chemotherapy for Gastric Cancer and Prognostic Value of Platelet–Lymphocyte Ratio in Patients Receiving XELOX

  2020cites this paper
• Platinum(IV) antitumor complexes and their nano-drug delivery

  2020cites this paper
• Resolving the Paradox of Colon Cancer Through the Integration of Genetics, Immunology, and the Microbiota

  2020cites this paper
• Irinotecan or Oxaliplatin: Which is the First Move for the Mate?

  2020cites this paper
• Oxaliplatin-Induced DHX9 Phosphorylation Promotes Oncogenic Circular RNA CCDC66 Expression and Development of Chemoresistance

  2020cites this paper
• Nano-scale imaging of dual stable isotope labeled oxaliplatin in human colon cancer cells reveals the nucleolus as a putative node for therapeutic effect

  2020cites this paper
• Cisplatin is more mutagenic than carboplatin or oxaliplatin at equitoxic concentrations

  2020cites this paper
• Quantitative evaluation of the intratumoral distribution of platinum in oxaliplatin‐treated rectal cancer: In situ visualization of platinum via synchrotron radiation X‐ray fluorescence spectrometry

  2019cites this paper
• MiRNA-204-5p and oxaliplatin-loaded silica nanoparticles for enhanced tumor suppression effect in CD44-overexpressed colon adenocarcinoma.

  2019cites this paper
• Identification of candidate genes and miRNAs for sensitizing resistant colorectal cancer cells to oxaliplatin and irinotecan

  2019cites this paper
• Natural products for treating colorectal cancer: A mechanistic review.

  2019cites this paper
• An oxaliplatin(iv) prodrug-based supramolecular self-delivery nanocarrier for targeted colorectal cancer treatment.

  2018cites this paper
• Can we downstage locally advanced pancreatic cancer to resectable? A phase I/II study of induction oxaliplatin and 5-FU chemoradiation.

  2018cites this paper
• Comparable effectiveness and immunomodulatory actions of oxaliplatin and cisplatin in electrochemotherapy of murine melanoma.

  2018cites this paper
• Evaluating the efficacy of liposomal delivery of nedaplatin in enhancing cytotoxicity, genotoxicity and DNA damage in lung, breast, and osteosarcoma cancer cell lines

  2018cites this paper
• Combination of Oxaliplatin and Vit.E-TPGS in Lipid Nanosystem for Enhanced Therapeutic Efficacy in Colon Cancers

  2018cites this paper
• The differences on efficacy of oxaliplatin in locally advanced colon cancer between mucinous and nonmucinous adenocarcinoma

  2018cites this paper
• Activated Integrated Stress Response Induced by Salubrinal Promotes Cisplatin Resistance in Human Gastric Cancer Cells via Enhanced xCT Expression and Glutathione Biosynthesis

  2018cites this paper
• Design, Synthesis and Biological Evaluation of Novel Estradiol-Triazole Analogs Targeting Epidermal Growth Factor Receptors in Colorectal Cancer

  2017influential citation
• Mise en évidence d’intéractions létales par criblage phénotypique dans le contexte de la résistance aux thérapies du cancer colorectal

  2017cites this paper
• Direct Determination of Metal Complexes' Interaction with DNA by Atomic Telemetry and Multiscale Molecular Dynamics.

  2017cites this paper
• DNA interaction with platinum-based cytostatics revealed by DNA sequencing.

  2017cites this paper
• Phase II study of preoperative concurrent chemoradiotherapy with oxaliplatin for locally advanced esophageal cancer

  2017cites this paper
• GLUT1-mediated selective tumor targeting with fluorine containing platinum(II) glycoconjugates

  2017cites this paper
• Synthesis, Characterization, and Time‐Dependent NMR Spectroscopy Studies of (SP‐4‐2)‐[(trans‐1R,2R/1S,2S‐15N2)‐Cyclohexane‐1,2‐diamine][(13C2)oxalato]platinum(II)

  2017cites this paper
• Cytotoxic platinum coordination compounds. DNA binding agents

  2017cites this paper
• Colon Cancer Cells Gene Expression Signature As Response to 5- Fluorouracil, Oxaliplatin, and Folinic Acid Treatment

  2016cites this paper
• Targeted nanoparticles for colorectal cancer.

  2016cites this paper
• Multiple nanoemulsion system for an oral combinational delivery of oxaliplatin and 5-fluorouracil: preparation and in vivo evaluation

  2016cites this paper
• Neurotoxische und neuroprotektive Mechanismen Cisplatin-induzierter Polyneuropathien

  2016cites this paper
• Esophagus Liver Stomach Colon Rectum Stage 0 Stage I Stage IV Stage II Stage III Blood vessel Lymph node future science group Review

  2016cites this paper
• The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs.

  2016cites this paper
• Nucleotide excision repair and response and survival to chemotherapy in colorectal cancer patients.

  2016cites this paper
• Toward a better understanding of the oxaliplatin mode of action upon the steric hindrance of 1,2-diaminocyclohexane and its analogue.

  2016cites this paper
• Hypermutation and unique mutational signatures of occupational cholangiocarcinoma in printing workers exposed to haloalkanes

  2016cites this paper
• Mechanistic basis of a combination D-penicillamine and platinum drugs synergistically inhibits tumor growth in oxaliplatin-resistant human cervical cancer cells in vitro and in vivo.

  2015cites this paper
• Phase I Clinical Trial of Ifosfamide, Oxaliplatin, and Etoposide (IOE) in Pediatric Patients With Refractory Solid Tumors

  2015influential citation
• 3D-DIP-Chip: a microarray-based method to measure genomic DNA damage

  2015cites this paper
• Platinum-induced kidney damage: Unraveling the DNA damage response (DDR) of renal tubular epithelial and glomerular endothelial cells following platinum injury.

  2015cites this paper
• Multidrug resistance-associated protein 2 (MRP2) and oxaliplatin transport

  2015cites this paper
• The potential role of Alu Y in the development of resistance to SN38 (Irinotecan) or oxaliplatin in colorectal cancer

  2015cites this paper
• Effect of chirality in platinum drugs

  2015cites this paper
• Cytotoxicity profile of novel sterically hindered platinum(II) complexes with (1R,2R)-N(1),N(2)-dibutyl-1,2-diaminocyclohexane.

  2015cites this paper
• Discovery of predictive biomarker candidates for intrinsic resistance to FOLFOX chemotherapy in colon cancer using a Top Down LC-MALDI approach -

  2015cites this paper
• ERCC1 Induction after Oxaliplatin Exposure May Depend on KRAS Mutational Status in Colorectal Cancer Cell Line: In Vitro Veritas

  2015cites this paper
• Computational modeling of miRNA-mediated gene regulation in consideration of miRNP binding information from AGO-bound CLIP-Seq data analysis

  2015cites this paper
• Chemotherapy-associated hepatotoxicity in colorectal cancer.

  2014cites this paper
• Chemotherapy-Associated Hepatotoxicity and Hepatic Resection for Metastatic Colorectal Cancer

  2014cites this paper
• Antitumor platinum(II) complexes of N-monoalkyl 1R,2R-diamino-cyclohexanes with 3-(nitrooxy)cyclobutane-1,1-dicarboxylate as a leaving group.

  2014cites this paper
• A Light‐Activated Metal Complex Targets both DNA and RNA in a Fluorescent in Vitro Transcription and Translation Assay

  2014cites this paper
• Cisplatin- vs. oxaliplatin-based radiosensitizing chemotherapy for squamous cell carcinoma of the esophagus

  2014cites this paper
• Cisplatin, oxaliplatin, and carboplatin unequally inhibit in vitro mRNA translation.

  2014cites this paper
• Colon cancer: cancer stem cells markers, drug resistance and treatment.

  2014cites this paper
• Measuring DNA damage and associated epigenetic changes genome-wide in cells following exposure to platinum analogue chemotherapeutic drugs

  2014cites this paper
• Large-scale modeling of condition-specific gene regulatory networks by information integration and inference

  2014cites this paper
• Oxaliplatin and Its Enantiomer Induce Different Condensation Dynamics of Single DNA Molecules

  2013cites this paper
• A multi‐center phase Ib study of oxaliplatin (NSC#266046) in combination with fluorouracil and leucovorin in pediatric patients with advanced solid tumors

  2013cites this paper
• Personalizing Colon Cancer Therapeutics: Targeting Old and New Mechanisms of Action

  2013cites this paper
• Characterisation of the interactions and biological impacts of cisplatin analogues and metallo-drug complexes with DNA

  2013cites this paper
• CYTOTOXIC PROPERTIES OF NOVEL PLATINUM COMPOUNDS, BBR3610-DACH AND TRANS-4-NBD IN TUMOR CELLS: CELLULAR EFFECTS OF 1, 2-DACH AND NBD LIGANDS

  2013cites this paper
• Chemotherapy induced hepatotoxicity in metastatic colorectal cancer: a review of mechanisms and outcomes.

  2013cites this paper
• Факултет медицинских наука , Универзитет у Крагујевцу Служба клиничке фармакологије , Клинички центар Крагујевац

  2013cites this paper
• Effects of oxaliplatin on mouse myenteric neurons and colonic motility

  2013cites this paper
• Spontaneous translocation of antitumor oxaliplatin, its enantiomeric analogue, and Cisplatin from one strand to another in double-helical DNA.

  2013cites this paper
• Chemotherapy-Induced Neuropathic Pain

  2012cites this paper
• Platinum-DNA interstrand crosslinks: molecular determinants of bending and unwinding of the double helix.

  2012cites this paper
• Identification and functional analysis of slowly cycling cells in colorectal cancer

  2012cites this paper
• Anticancer Activity of Methyl-Substituted Oxaliplatin Analogs

  2012cites this paper
• Pharmacogenomic Analysis Identifies Increased Efficacy of Oxaliplatin in ABCB1 Overexpressing Tumors

  2012cites this paper
• Avaliação da resistência de células-tronco derivadas de tecido adiposo humano a quimioterápicos

  2012cites this paper
• Phase I pilot study of oxaliplatin, infusional 5-FU, and cetuximab in recurrent or metastatic head and neck cancer

  2012cites this paper
• From amino acids to proteins as targets for metal-based drugs.

  2012cites this paper
• Debio 0507 primarily forms diaminocyclohexane-Pt-d(GpG) and -d(ApG) DNA adducts in HCT116 cells

  2012cites this paper
• Revisiting [PtCl₂(cis-1,4-DACH)]: an underestimated antitumor drug with potential application to the treatment of oxaliplatin-refractory colorectal cancer.

  2012cites this paper
• Safety analysis of FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies.

  2012cites this paper
• Strategies of targeting oral drug delivery systems to the colon and their potential use for the treatment of colorectal cancer

  2012cites this paper
• Structures of oxaliplatin-oligonucleotide adducts from DNA.

  2012cites this paper
• Cancer Chemotherapy-Induced Neuropathic Pain: The Underlying Peripheral Neuropathy

  2012cites this paper
• The role of the organic cation/carnitine transporters in the uptake and neurotoxicity of oxaliplatin

  2012cites this paper